Monjuvi (tafasitamab) targets the CD-19, a protein on the surface of B-cells that is also targeted by Amgen’s bispecific antibody Blincyto (blinatumomab) for acute lymphoblastic leukaemia (ALL ...

Incyte has a strong track record of revenue growth and a robust pipeline, targeting over 10 high-impact product launches by ...

Incyte says 2025 is expected to be a year of defining catalysts with four launches, four pivotal study readouts, at least ...

These are Zynyz (retifanlimab) for the treatment of squamous cell anal carcinoma (SCAC), Monjuvi (tafasitamab) for follicular lymphoma, and Opzelura (ruxolitinib) cream. A supplemental NDA has ...